Also known as
Other names:
- Metenolone acetate
- Metenolone enanthate
- Methenolone 1-dehydrotestosterone
- Primobolan
Therapeutic Goods Administration (TGA) approval
Metenolone is not listed on the Australian Register of Therapeutic Goods (ARTG).
World Anti-Doping Code Prohibited List 2026
Metenolone is a prohibited substance listed under S1.1 Anabolic Androgenic Steroids (AAS).
S1 Anabolic Agents are prohibited at all times and are non-specified substances.
This substance meets at least two of the following three criteria, as determined by the World Anti-Doping Agency (WADA);
- It has the potential to enhance or does enhance sports performance
- It poses an actual or potential health risk to the athlete
- It violates the spirit of sport (as defined in The Code).
|
Check medications, find batch-tested supplements and more:
Download the Sport Integrity App
|
What is it?
Metenolone is a synthetic long-acting anabolic androgenic steroid. It is a derivative of dihydrotestosterone.
Metenolone was originally developed in the early 1960s to treat muscle-wasting conditions and anemia, currently not approved for therapeutic uses in Australia.
It is currently listed under appendix D of the poison standard.
Possession without authority is illegal.
How does it work?
Metenolone works by binding to the androgen receptors in the body and stimulates protein synthesis to promote muscle growth.
Uses
Anabolic Androgenic Steroids such as Metenolone and its metabolites increase muscle growth and lean body mass.
Adverse Health Effects and Risk
Anabolic agents pose many threats to an athlete’s health.
Some side effects may include:
- Increased blood pressure and cholesterol levels, which can lead to heart disease
- Liver disease
- Infertility can also result from the use of these agents, as it can suppress the body's natural production of testosterone.
What if an athlete has been prescribed Metenolone for a medical condition?
A Therapeutic Use Exemption (TUE) would not be granted for the use of metenolone.
Please see link for more information regarding Therapeutic Use Exemptions.